I-SPY Clinical Sites

Widely hailed as the future of phase II drug development, the adaptive I-SPY2 platform trial has set a new benchmark for efficiency, through innovation in trial design and clinical operations.
Columbia University
Georgetown University
Loyola University
Masonic Cancer Center, University of Minnesota
Mayo Clinic
Moffitt Cancer Center
Oregon Health & Science University
Swedish Cancer Institute
UAB
UCSD
UCSF
USC
University of Chicago
University of Colorado, Denver
University of Pennsylvania
Yale